207 related articles for article (PubMed ID: 23062244)
21. Anti-tubercular drug designing by structure based screening of combinatorial libraries.
Ghosh P; Bagchi MC
J Mol Model; 2011 Jul; 17(7):1607-20. PubMed ID: 20953648
[TBL] [Abstract][Full Text] [Related]
22. In silico discovery and virtual screening of multi-target inhibitors for proteins in Mycobacterium tuberculosis.
Speck-Planche A; Kleandrova VV; Luan F; Cordeiro MN
Comb Chem High Throughput Screen; 2012 Sep; 15(8):666-73. PubMed ID: 22452349
[TBL] [Abstract][Full Text] [Related]
23. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
[TBL] [Abstract][Full Text] [Related]
24. Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR.
van Doorn HR; An DD; de Jong MD; Lan NT; Hoa DV; Quy HT; Chau NV; Duy PM; Tho DQ; Chinh NT; Farrar JJ; Caws M
Int J Tuberc Lung Dis; 2008 Jul; 12(7):736-42. PubMed ID: 18544197
[TBL] [Abstract][Full Text] [Related]
25. Fluoroquinolone consumption and -resistance trends in Mycobacterium tuberculosis and other respiratory pathogens: Ecological antibiotic pressure and consequences in Pakistan, 2009-2015.
Shakoor S; Tahseen S; Jabeen K; Fatima R; Malik FR; Rizvi AH; Hasan R
Int J Mycobacteriol; 2016 Dec; 5(4):412-416. PubMed ID: 27931682
[TBL] [Abstract][Full Text] [Related]
26. A model to predict anti-tuberculosis activity: value proposition for marine microorganisms.
Liu M; Grkovic T; Zhang L; Liu X; Quinn RJ
J Antibiot (Tokyo); 2016 Aug; 69(8):594-9. PubMed ID: 27406906
[TBL] [Abstract][Full Text] [Related]
27.
Taira J; Ito T; Nakatani H; Umei T; Baba H; Kawashima S; Maruoka T; Komatsu H; Sakamoto H; Aoki S
Int J Mycobacteriol; 2017; 6(2):142-148. PubMed ID: 28559515
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, biological evaluation, structure-activity relationship, and toxicity of clinafloxacin-azole conjugates as novel antitubercular agents.
Liu J; Ren Z; Fan L; Wei J; Tang X; Xu X; Yang D
Bioorg Med Chem; 2019 Jan; 27(1):175-187. PubMed ID: 30522898
[TBL] [Abstract][Full Text] [Related]
29. Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.
Mamatha HG; Shanthi V
J Glob Antimicrob Resist; 2018 Mar; 12():5-10. PubMed ID: 28887289
[TBL] [Abstract][Full Text] [Related]
30. Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
Coulibaly S; Cimino M; Ouattara M; Lecoutey C; Buchieri MV; Alonso-Rodriguez N; Briffotaux J; Mornico D; Gicquel B; Rochais C; Dallemagne P
Eur J Med Chem; 2020 Dec; 207():112821. PubMed ID: 32950907
[TBL] [Abstract][Full Text] [Related]
31. Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy.
Sgaragli G; Frosini M; Saponara S; Corelli F
Curr Med Chem; 2016; 23(21):2245-74. PubMed ID: 27142291
[TBL] [Abstract][Full Text] [Related]
32. Drug resistance in Mycobacterium tuberculosis: molecular mechanisms challenging fluoroquinolones and pyrazinamide effectiveness.
Miotto P; Cirillo DM; Migliori GB
Chest; 2015 Apr; 147(4):1135-1143. PubMed ID: 25846529
[TBL] [Abstract][Full Text] [Related]
33. Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs.
Blanco D; Perez-Herran E; Cacho M; Ballell L; Castro J; González Del Río R; Lavandera JL; Remuiñán MJ; Richards C; Rullas J; Vázquez-Muñiz MJ; Woldu E; Zapatero-González MC; Angulo-Barturen I; Mendoza A; Barros D
Antimicrob Agents Chemother; 2015 Apr; 59(4):1868-75. PubMed ID: 25583730
[TBL] [Abstract][Full Text] [Related]
34. Fuzzy Comprehensive Evaluation Assistant 3D-QSAR of Environmentally Friendly FQs to Reduce ADRs.
Ren Z; Wang Y; Xu H; Li Y; Han S
Int J Environ Res Public Health; 2019 Aug; 16(17):. PubMed ID: 31470687
[TBL] [Abstract][Full Text] [Related]
35. In silico approaches and chemical space of anti-P-type ATPase compounds for discovering new antituberculous drugs.
Santos P; López-Vallejo F; Soto CY
Chem Biol Drug Des; 2017 Aug; 90(2):175-187. PubMed ID: 28111912
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in QSAR-based identification and design of anti-tubercular agents.
Nidhi ; Siddiqi MI
Curr Pharm Des; 2014; 20(27):4418-26. PubMed ID: 24245761
[TBL] [Abstract][Full Text] [Related]
37. Virtual generation of agents against Mycobacterium tuberculosis. A QSAR study.
Besalú E; Ponec R; de Julián-Ortiz JV
Mol Divers; 2003; 6(2):107-20. PubMed ID: 14761161
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of fluoroquinolone resistance in Mycobacterium tuberculosis.
Zhang YJ; Li XJ; Mi KX
Yi Chuan; 2016 Oct; 38(10):918-927. PubMed ID: 27806933
[TBL] [Abstract][Full Text] [Related]
39. Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase.
Sriram D; Aubry A; Yogeeswari P; Fisher LM
Bioorg Med Chem Lett; 2006 Jun; 16(11):2982-5. PubMed ID: 16554151
[TBL] [Abstract][Full Text] [Related]
40. Combined 2D-QSAR, Principal Component Analysis and Sensitivity Analysis Studies on Fluoroquinolones' Genotoxicity.
Du M; Zhang D; Hou Y; Zhao X; Li Y
Int J Environ Res Public Health; 2019 Oct; 16(21):. PubMed ID: 31661905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
